S Kant Healthcare

What S Kant Healthcare does

S Kant Healthcare Ltd. is an India-based pharmaceutical company founded in 1996 and headquartered in Mumbai, operating as a single-site EU-GMP certified and WHO-Prequalified manufacturer of finished formulations across oral solids (tablets, capsules), oral liquids (syrups, solutions, suspensions), and semi-solids (ointments, creams, gels). The company's manufacturing campus in Vapi, Gujarat spans 11 acres and supports annual capacity of 3.5 billion tablets, 600 million capsules, 75 million oral liquid bottles, and 100 million semi-solid tubes, with 50% of site power supplied by a captive solar plant. A 15,000 sq.ft independent R&D center in Navi Mumbai houses 100+ scientists focused on formulation development, exhibit batch manufacturing, and scale-up under GMP conditions.

The business operates a hybrid B2B model combining contract development and manufacturing organization (CDMO) services, having executed 75 projects, with branded generic Essential Medicines supply across 85+ countries, including 8 WHO-Prequalified products for Malaria and Tuberculosis distributed to global health institutions and NGOs. Revenue is generated through development fees, technology transfer services, commercial contract manufacturing, and product sales across regulated and emerging markets. The company is part of SK Group, a family-owned diversified pharmaceutical conglomerate established in 1932, which provides backward integration through in-house API manufacturing across six sites, as well as group logistics handling 25,000+ SKUs. The group reports aggregate turnover exceeding USD 250 million across its entities.

S Kant Healthcare markets primarily through enterprise field sales and industry events (notably CPHI Worldwide 2025), with a relationship-led model where customer interactions are personally managed by SK Family members. The customer base spans global pharmaceutical companies (CDMO clients), global health institutions and NGOs (WHO Essential Medicines), and emerging-market distributors across Africa, Asia, and Latin America. The company has established dedicated offices in Nigeria and Burkina Faso, active marketing teams in East Africa, an upcoming manufacturing site in Uganda for the 'Make in Africa for Africa' initiative, and a sub-brand DermX-Expect Excellence targeting the Indian aesthetic dermatology market.

Name

S Kant Healthcare

Legal name

S Kant Healthcare Ltd.

Website

https://skant.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

S Kant Healthcare is a Mumbai-based, family-owned pharmaceutical manufacturer and CDMO offering EU-GMP and WHO-Prequalified finished formulations (oral solids, liquids, semi-solids) with 1,000+ employees and a Vapi manufacturing campus serving 85+ countries including global pharma CDMO clients, NGOs, and emerging-market distributors.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Contract development manufacturing
• Finished formulations
• Essential medicines supply
• Generic pharmaceuticals

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Organization (CDMO): End-to-end contract development and manufacturing services for regulated and emerging pharmaceutical markets. Revenue generated through development fees, technology transfer services, and manufacturing of finished formulations for client companies.
2. Finished Formulations Manufacturing: Manufacturing and supply of generic pharmaceutical products including Essential Medicines, products for chronic and acute care needs across multiple therapeutic categories. Revenue from product sales to global institutions, NGOs, and distribution partners.
3. API Manufacturing: Backward integration through in-house Active Pharmaceutical Ingredient (API) manufacturing within SK Group. Revenue from API sales and integrated supply chain services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

S Kant Healthcare is an EU-GMP certified and WHO-Prequalified finished formulation pharmaceutical manufacturer offering contract development and manufacturing (CDMO) services and own generic pharmaceutical products across oral solids, oral liquids, and semi-solids. Its single-site manufacturing campus in Vapi, Gujarat, supported by an independent R&D center in Navi Mumbai and backward-integrated API manufacturing through SK Group, supplies Essential Medicines and chronic/acute care products to global pharmaceutical companies, NGOs, and global health institutions across 85+ countries.

Product overview

S Kant Healthcare is a single-site pharmaceutical manufacturer offering a unified portfolio of finished formulations and CDMO services. The core offering consists of oral solids (tablets, capsules, dry powders), oral liquids (syrups, solutions, suspensions), and semi-solids (ointments, creams, gels, oral gel), all manufactured at their EU-GMP and WHO-PQ certified facility in Vapi, Gujarat. The company supplements its formulation business with in-house API manufacturing through backward integration with the SK Group. Additionally, the DermX sub-brand extends the portfolio into aesthetic dermatology for the Indian market. Products are distributed as Essential Medicines (including WHO Prequalified items for Malaria and TB) and chronic/acute care formulations across 85+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• DermX: Aesthetic dermatology division launched in the Indian market, ethically marketed through DermX-Expect Excellence. Products are co-created with leading dermatologists.

Products and services

• Essential Medicines Portfolio Life-saving generic pharmaceuticals featured on the WHO Essential Medicines List, including WHO Prequalified products for Malaria and Tuberculosis, supplied to global institutions, NGOs, and distribution partners.
• CDMO Services
• Oral Solids Manufacturing (Tablets, Capsules, Dry Powders)
• Oral Liquids Manufacturing (Syrups, Solutions, Suspensions)
• Semi-Solids Manufacturing (Ointments, Creams, Gels)
• DermX Aesthetic Dermatology Products
• Active Pharmaceutical Ingredients (APIs)

Quantifiable outcome

• 3.5 Bil Units tablet capacity, 600 Mil Units capsule capacity annually
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and major.

• SK Group (Parent Company)coreStrategic or Co-development PartnerS Kant Healthcare is part of SK Group, established in 1932. SK Group provides strategic oversight, shared services, and integration across multiple pharmaceutical entities including API manufacturing sites. The relationship enables backward integration and supply chain advantages.
• DermX Division Partners (Dermatologists)coreStrategic or Co-development PartnerDermatological products co-created with leading dermatologists for the Indian market. Represents S Kant's foray into aesthetic dermatology through its DermX-Expect Excellence division.
• Large Global InstitutionsmajorChannel Partner/ Reseller/ DistributorCollaborates with large global institutions for supply of WHO Essential Medicines. Products featured on WHO Essential Medicines List (EML) support global public health initiatives.
• Non-governmental Organizations (NGOs)majorChannel Partner/ Reseller/ DistributorPartnership with NGOs for distribution of WHO Prequalified products to combat Malaria and Tuberculosis in developing regions.
• Anuh Pharma Ltd.coreOthersBSE-listed bulk drug manufacturer and part of SK Group. SK Group generates over 250 Million USD turnover through its various practices including this entity.
• Eskay Iodine Pvt. Ltd.coreOthersGMP and US FDA-approved greenfield project with strong India presence and global reach. Part of SK Group.
• SK LogisticscoreOthersOne-stop solution for pharmaceutical warehousing and repackaging needs. Handles and distributes 25000+ SKUs worth more than USD 1 Billion.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Syngene International: Indian CRDMO offering contract research, development, and manufacturing services to global pharma. Comparable as a CDMO serving global pharmaceutical clients, though more focused on biologics and earlier-stage development work.
• Aurobindo Pharma: Large Indian generics and API manufacturer with global distribution and WHO-Prequalified product portfolio. Comparable WHO-PQ credentials and emerging market essential medicines exposure, though at much larger scale.

Direct peers

• Granules India: Indian pharmaceutical manufacturer specializing in high-volume generic finished formulations and APIs with significant CDMO exposure. Overlaps with S Kant on oral solid generics, API integration, and emerging market distribution.
• Strides Pharma Science: Indian generics manufacturer with strong presence in Africa and emerging markets, plus contract manufacturing capabilities. Comparable emerging-market distribution footprint and generic finished formulation model.
• Piramal Pharma Solutions: Global CDMO offering contract development and manufacturing across finished dosage forms with strong regulatory credentials. Directly comparable to S Kant's CDMO service model targeting regulated markets and global pharma partners.
• Natco Pharma: Indian pharmaceutical company with API and finished formulation capabilities serving regulated and emerging markets. Comparable WHO-PQ-eligible generics portfolio and global health channel presence.
• Laurus Labs: Indian integrated pharma company with API manufacturing and CDMO/formulations business serving global markets. Comparable API-to-formulation backward integration and finished dosage CDMO capabilities.
• Divis Laboratories: Leading Indian API and CDMO player offering contract development and manufacturing services to global pharmaceutical companies. Highly comparable to S Kant's CDMO and API integration model, though at significantly larger scale and with broader capabilities.
• Morepen Laboratories: Indian pharmaceutical manufacturer producing APIs and finished formulations with focus on affordable generics. Comparable API and finished formulation integrated model with similar emerging market orientation.
• Jubilant Pharmova (CDMO division): Indian pharma and CDMO player offering contract development and manufacturing services across multiple dosage forms with global regulatory certifications. Comparable CDMO offerings targeting regulated and emerging markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/s-kant-healthcare-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about S Kant Healthcare